Coagulation markers in diagnostic and monitoring of thromboembolic complication in COVID-19

Authors

  • Magdalena Czarnecka-Czapczyńska Department of Internal Medicine, Angiology and Physical Medicine, Centre for Laser Diagnostics and Therapy, Medical University of Silesia in Katowice, Bytom, Poland
  • Dorota Bartusik-Aebisher Department of Biochemistry and General Chemistry, Medical College of the University of Rzeszow, University of Rzeszow, Rzeszow, Poland https://orcid.org/0000-0002-5557-5464
  • Magdalena Krupka-Olek Department of Internal Medicine, Angiology and Physical Medicine, Centre for Laser Diagnostics and Therapy, Medical University of Silesia in Katowice, Bytom, Poland; Clinical Department of Internal Medicine, Dermatology and Allergology, Medical University of Silesia, Katowice, Zabrze, Poland
  • David Aebisher Department of Biochemistry and General Chemistry, Medical College of the University of Rzeszow, University of Rzeszow, Rzeszow, Poland https://orcid.org/0000-0002-2661-6570
  • Grzegorz Cieślar Department of Internal Medicine, Angiology and Physical Medicine, Centre for Laser Diagnostics and Therapy, Medical University of Silesia in Katowice, Bytom, Poland https://orcid.org/0000-0003-2210-8744
  • Wojciech Latos Department of Internal Medicine, Angiology and Physical Medicine, Centre for Laser Diagnostics and Therapy, Medical University of Silesia in Katowice, Bytom, Poland
  • Aleksandra Kawczyk-Krupka Department of Internal Medicine, Angiology and Physical Medicine, Centre for Laser Diagnostics and Therapy, Medical University of Silesia in Katowice, Bytom, Poland https://orcid.org/0000-0003-1284-3809

DOI:

https://doi.org/10.15584/ejcem.2021.3.5

Keywords:

anticoagulation, coagulation abnormalities, COVID-19

Abstract

Abstract

Introduction. Coronavirus disease 2019 (COVID-19) was first observed in China in Wuhan city, Hubei province in December, 2019, and specified as a pandemic by the World Health Organization (WHO). COVID-19 is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARSCoV2).

Aim. The aim of this article is to discuss epidemiology of thromboembolic complication in COVID-19.

Material and methods. This article is a review done in regards to discuss clinical features of the anticoagulation treatment in COVID-19.

Analysis of the literature. A review is discussed an anticoagulation treatment in 41 manuscripts.

Conclusion. Most commonly coagulation abnormalities in patient with COVID-19 is mild thrombocytopenia. Apart from their typical role in thrombosis and hemostasis, platelets mediate key aspects of immune and inflammatory.

Downloads

Download data is not yet available.

References

Hadid T, Kafri Z, Al-Katib A. Coagulation and anticoagulation in COVID-19. Blood Rev. 2021;47:100761.

Beun R, Kusadasi N, Sikma M, Westerink J, Huisman A. Thromboembolic events and apparent heparin resistance in patients infected with SARS-CoV-2. Int J Lab Hematol. 2020;42(1):19-20.

Alsharif W, Qurashi A. Effectiveness of COVID-19 diagnosis and management tools: A review. Radiography (Lond). 2021;27(2):682-687.

Bikdeli B, Madhavan MV, Jimenez D, et al. Global COVID-19 Thrombosis Collaborative Group, Endorsed by the ISTH, NATF, ESVM, and the IUA, Supported by the ESC Working Group on Pulmonary Circulation and Right Ventricular Function. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;75(23):2950-2973.

Giannis D, Ziogas IA, Gianni P. Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. J Clin Virol. 2020;127:104362.

Terpos E, Ntanasis-Stathopoulos I, Elalamy I, et al. Hematological findings and complications of COVID-19. Am J Hematol. 2020;95(7):834-847.

Liao YC, Liang WG, Chen FW, Hsu JH, Yang JJ, Chang MS. IL‐19 induces production of IL‐6 and TNF‐alpha and results in cell apoptosis through TNF‐alpha. J Immunol. 2002;169(8):4288‐4297.

Middeldorp S, Coppens M, van Haaps TF, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020;18(8):1995-2002.

Lodigiani C, Iapichino G, Carenzo L. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Humanitas COVID-19 Task Force Thromb Res. 2020;191:9-14.

Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost 2020;18:1421-1424.

Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145-147.

Klok FA, Kruip MJHA, Van Der Meer NJM, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. Thromb Res. 2020;191:148-150.

Chojnowski K. Dimer D – diagnostyczny i rokowniczy marker żylnej choroby zakrzepowo-zatorowej. Hematologia. 2010;1,2:102-108.

Marchandot B, Sattler L, Jesel L, et al. COVID-19 Related Coagulopathy: A Distinct Entity? J. Clin. Med. 2020;9:1651.

Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054-1062.

Li Y, Zhao K, Wei H, et al. Dynamic relationship between D-dimer and COVID-19 severity. Br J Haematol. 2020;190(1):e24-e27.

Li C, Hu B, Zhang Z, et al. D-dimer triage for COVID-19. Acad Emerg Med. 2020;27(7):612-613.

Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844-847.

Al-Samkari H, Karp Leaf RS, Dzik WH, et al. COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood. 2020;136(4):489-500.

Artifoni M, Danic G, Gautier G, et al. Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors. J Thromb Thrombolysis 2020;50(1):211-216.

Pathak A, Agrawal A. Evolution of C-Reactive Protein. Front Immunol. 2019;10:943.

Ponti G, Maccaferri M, Ruini C, Tomasi A, Ozben T. Biomarkers associated with COVID-19 disease progression. Crit Rev Clin Lab Sci. 2020;57(6):389-399.

Tu TM, Goh C, Tan YK, et al. Cerebral Venous Thrombosis in Patients with COVID-19 Infection: a Case Series and Systematic Review. J Stroke Cerebrovasc Dis. 2020;29(12):105379.

Wang W, Sun Q, Bao Y, et al. Analysis of Risk Factors for Thromboembolic Events in 88 Patients with COVID-19 Pneumonia in Wuhan, China: A Retrospective Descriptive Report. Med Sci Monit. 2021;27:e929708.

Erdoes G, Koster A, Meesters MI, et al. The role of fibrinogen and fibrinogen concentrate in cardiac surgery: an international consensus statement from the Haemostasis and Transfusion Scientific Subcommittee of the European Association of Cardiothoracic Anaesthesiology. Anaesthesia. 2019;74(12):1589-1600.

Thachil J, Agarwal S. Understanding the COVID-19 coagulopathy spectrum. Anaesthesia. 2020;75(11):1432-1436.

Ng LF, Hibberd ML, Ooi EE, et al. A human in vitro model system for investigating genome-wide host responses to SARS coronavirus infection. BMC Infect Dis. 2004;4:34.

Zou Y, Guo H, Zhang Y. Analysis of coagulation parameters in patients with COVID-19 in Shanghai, China. Biosci Trends. 2020;14(4):285-289.

Manne BK, Denorme F, Middleton EA, et al. Platelet gene expression and function in patients with COVID-19. Blood. 2020;136(11):1317-1329.

Semple JW, Italiano JE Jr., Freedman J. Platelets and the immune continuum. Nat Rev Immunol. 2011;11(4):264-274.

Connors JM, Levy JH. COVID-19 an its implications for thrombosis and anticoagulation. Blood. 2020;135(23):2033-2040.

Becker RC. COVID-19 update: Covid-19-associated coagulopathy. J Thromb Thrombolysis. 2020;50(1):54-67.

Iba T, Levy JH, Levi M, Thachil J. Koagulopatia w COVID-19. J Thromb Haemost. 2020;18:2103-2109.

Bertolin AJ, Dalçóquio TF, Salsoso R , et al. . Platelet Reactivity and Coagulation Markers in Patients with COVID-19. Adv Ther. 2021;38(7):3911-3923.

Mucha SR, Dugar S, McCrae K, et al. Coagulopathy in COVID-19: manifestations and management. Cleve Clin J Med. 2020;87(8):461-468.

Ranucci M, Ballotta A, Di Dedda U, et al. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. J. Thromb. Haemost. 2020;18(7):1747-1751.

Ganguly P, Alam SF. Role of homocysteine in the development of cardiovascular disease. Nutr J. 2015;14:6.

Ponti G, Ruini C, Tomasi A. Homocysteine as a potential predictor of cardiovascular risk in patients with COVID-19. Med Hypotheses. 2020;143:109859.

Yang X, Yang Q, Wang Y, et al. Thrombocytopenia and its association with mortality in patients with COVID-19. J Thromb Haemost. 2020;18(6):1469-1472.

Todua F, Akhvlediani M, Vorobiova E, Tsivtsivadze G, Baramidze A. Homocysteine and D-dimer levels and multilayer computed tomography for diagnosing pulmonary artery thromboembolism. Vessel Plus. 2017;1:38-42.

Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;46(6):1089-1098.

Downloads

Published

2021-09-30

How to Cite

Czarnecka-Czapczyńska, M., Bartusik-Aebisher, D., Krupka-Olek, M., Aebisher, D., Cieślar, G., Latos, W., & Kawczyk-Krupka, A. (2021). Coagulation markers in diagnostic and monitoring of thromboembolic complication in COVID-19. European Journal of Clinical and Experimental Medicine, 19(3), 241–245. https://doi.org/10.15584/ejcem.2021.3.5

Issue

Vol. 19 No. 3 (2021)

Section

REVIEW PAPERS

License

Copyright (c) 2021 European Journal of Clinical and Experimental Medicine

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.

All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.

Most read articles by the same author(s)

<< < 1 2 3 4 5 > >>